Payment overview · 2025
General Payments
$1,098.24
62 reported records · 22 companies
Healthcare provider profile · identity verified
Brett L Ferrell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TULLAHOMA, TN · NPI 1356646434
Verified facts
What the public records show
CMS Open Payments records show Brett L Ferrell, M.D. received $1,098.24 in general payments during 2025 across 62 reported records.
Novo Nordisk Inc accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.77 | 17.4% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.85 | 10.8% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.19 | 10.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.52 | 8.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.60 | 6.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.57 | 5.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.90 | 5.4% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.03 | 4.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.29 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.09 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $37.01 | 3.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.91 | 3.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $29.27 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.07 | 2.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.02 | 2.0% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.96 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.70 | 1.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.20 | 1.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.76 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.54 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.48 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.51 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,098.24 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $155.86 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.14 | 11 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $110.19 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.41 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.17 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.57 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $58.90 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $47.03 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.64 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 379 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
98 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
379 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 589 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 103 |
| Eliquis | Apixaban | 379 | 59 |
| Losartan Potassium | Losartan Potassium | 365 | 103 |
| Furosemide | Furosemide | 357 | 89 |
| Gabapentin | Gabapentin | 351 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 83 |
| Lisinopril | Lisinopril | 297 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 278 | 74 |
| Omeprazole | Omeprazole | 263 | 78 |
| Metformin Hcl | Metformin Hcl | 252 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 64 |
| Alprazolam | Alprazolam | 203 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 191 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 21 |
| Montelukast Sodium | Montelukast Sodium | 156 | 46 |
| Doxycycline Hyclate | Doxycycline Hyclate | 150 | 117 |
| Potassium Chloride | Potassium Chloride | 150 | 48 |
| Trazodone Hcl | Trazodone Hcl | 144 | 37 |
| Carvedilol | Carvedilol | 140 | 46 |
| Famotidine | Famotidine | 136 | 49 |
| Donepezil Hcl | Donepezil Hcl | 125 | 27 |
| Allopurinol | Allopurinol | 120 | 28 |
| Methylprednisolone | Methylprednisolone | 120 | 90 |
| Nifedipine Er | Nifedipine | 118 | 29 |
| Simvastatin | Simvastatin | 115 | 26 |
| Ozempic | Semaglutide | 114 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 27 |
| Tramadol Hcl | Tramadol Hcl | 107 | 21 |
| Trulicity | Dulaglutide | 98 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 88 | 32 |
| Farxiga | Dapagliflozin Propanediol | 86 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 34 |
| Buspirone Hcl | Buspirone Hcl | 84 | 29 |
| Alendronate Sodium | Alendronate Sodium | 81 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 26 |
| Meloxicam | Meloxicam | 77 | 35 |
| Levetiracetam | Levetiracetam | 75 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Spironolactone | Spironolactone | 75 | 19 |
| Pregabalin | Pregabalin | 74 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 19 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Lorazepam | Lorazepam | 73 | 15 |
| Mirtazapine | Mirtazapine | 73 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 14 |
| Xarelto | Rivaroxaban | 70 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 22 |
| Cefdinir | Cefdinir | 66 | 50 |
| Promethazine Hcl | Promethazine Hcl | 64 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 12 |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Novolog Flexpen | Insulin Aspart | 60 | 13 |
| Finasteride | Finasteride | 59 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 15 |
| Lactulose | Lactulose | 58 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 19 |
| Prednisone | Prednisone | 55 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 42 |
| Atenolol | Atenolol | 52 | 17 |
| Celecoxib | Celecoxib | 52 | 12 |
| Clonidine Hcl | Clonidine Hcl | 51 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 50 | 11 |
| Bupropion Xl | Bupropion Hcl | 49 | 13 |
| Meclizine Hcl | Meclizine Hcl | 49 | 17 |
| Jardiance | Empagliflozin | 48 | 14 |
| Nystatin | Nystatin | 47 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Azithromycin | Azithromycin | 44 | 37 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 14 |
| Ezetimibe | Ezetimibe | 43 | 12 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 23 |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Sucralfate | Sucralfate | 39 | 16 |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 29 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 12 |
| Valacyclovir | Valacyclovir Hcl | 35 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 11 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 17 |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 13 |
| Digoxin | Digoxin | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 12 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Benzonatate | Benzonatate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ritonavir | Ritonavir | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Darunavir | Darunavir | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,098.24 · 62 records | Novo Nordisk Inc | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, JARDIANCE, JASCAYD, JATENZO, KISUNLA, Kerendia, MINIMED 780G, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PROLIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tlando, UBRELVY, VERQUVO, VRAYLAR, Veozah, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error